Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Twist Bioscience Corporation (TWST) has filed a Form 144 notice covering the potential sale of 3,189 common shares through Fidelity Brokerage, with an estimated market value of $90,453. The proposed trade window opens on 04 Aug 2025. The company reports 59,916,141 shares outstanding, so the planned sale represents roughly 0.005 % of the float—immaterial at the corporate level.
The shares derive from restricted-stock that vested on 01 Aug 2025 and are held in the account of Patrick Finn. Over the previous three months, Finn has already sold 27,118 shares for total gross proceeds of $894,853, indicating an ongoing disposition program.
Form 144 is only a notice; execution, timing, and price may vary, and the filer certifies no undisclosed material adverse information. No operating, earnings or guidance data accompany this filing.
Twist Bioscience Corp. (TWST) – Form 144 filing discloses that insider Patrick Finn plans to sell 2,232 common shares through Fidelity Brokerage on or about 23 Jul 2025. At the stated market value of $79,773, the proposed sale equals roughly 0.004% of the company’s 59.9 million shares outstanding.
The notice also lists five prior sales by Finn during the last three months, totaling 26,944 shares and $897,390 in gross proceeds (dates: 23 Apr, 5 May, 8 May, 21 May, 2 Jul 2025). The shares were acquired via restricted-stock vesting on 22 Jul 2025, indicating compensation-related disposal rather than open-market buying and selling. By signing Form 144, the filer attests to possessing no undisclosed adverse information.
Though the absolute size is small, the continued disposition may signal a modestly negative insider sentiment trend that investors could monitor.